Colorectal carcinomas, KRAS p.G13D mutant allele-specific imbalance, and anti-epidermal growth factor receptor therapy

Cancer

Volumn 119, Issue 24, 2013, Pages 4366-

  Hartman, Douglas J ^a   Chiosea, Simion I ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GLYCINE; K RAS PROTEIN;

ALLELE; CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CHROMOSOME 12; CHROMOSOME DISORDER; CODON; COLORECTAL CARCINOMA; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE MUTATION; GENETIC DISORDER; HUMAN; KRAS GENE; LETTER; METASTASIS POTENTIAL; MUTANT ALLELE SPECIFIC IMBALANCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84889878639     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28371     Document Type: Letter

References (4)

1. Woo J, Palmisiano N, Tester W, Leighton JC Jr,. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer. 2013; 119: 1941-1950.
2. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304: 1812-1820.
3. Hartman DJ, Davison JM, Foxwell TJ, Nikiforova MN, Chiosea SI,. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival. Int J Cancer. 2012; 131: 1810-1817.
4. Soh J, Okumura N, Lockwood WW, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PloS One. 2009; 4: e7464.